What one share of Dyne Therapeutics holds
We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS.
Dyne Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.35 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.10 |
| Cash and investments | $4.08 |
| Debt | $1.20 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$6.08 | $0.67 | −$5.52 | — | $5.43 |
| 2020 | — | −$4.13 | $0.08 | −$3.31 | — | — |
| 2021 | — | −$2.93 | $0.07 | −$2.42 | — | $7.14 |
| 2022 | — | −$3.23 | $0.06 | −$3.01 | — | $4.54 |
| 2023 | — | −$3.95 | $0.01 | −$3.16 | — | $1.49 |
| 2024 | — | −$3.37 | $0.03 | −$3.13 | — | $6.16 |
| 2025 | — | −$3.47 | $0.01 | −$3.15 | — | $5.89 |
Common questions about Dyne Therapeutics
How much does one share of Dyne Therapeutics earn?
Over the last 12 months, Dyne Therapeutics lost $3.35 for each share.
Does Dyne Therapeutics pay a dividend?
Dyne Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Dyne Therapeutics’s book value per share?
Dyne Therapeutics’s book value is $4.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Dyne Therapeutics have?
Each share of Dyne Therapeutics has $4.08 of cash and investments and $1.20 of debt, as of June 30, 2026.
What is Dyne Therapeutics’s free cash flow per share?
−$3.10 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Dyne Therapeutics bought back shares?
Dyne Therapeutics’s share count rose about 5164% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.